课题基金 / 基金详情

ABT 538 VS AZT VS ABT 538 AND AZT IN HIV+ PATIENTS WITHOUT PRIOR THERAPY

ABT 538 VS AZT VS ABT 538 AND AZT IN HIV+ PATIENTS WITHOUT PRIOR THERAPY
ABT 538 与 AZT 对比 ABT 538 和 AZT 在未经既往治疗的 HIV 患者中的情况
批准号：
6246943
负责人：
Martin H Markowitz
金额：
$5.86万
依托单位：
ROCKEFELLER UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-01-27 至 1997-11-30
来源：
https://reporter.nih.gov/project-details/6246943
关键词：
AIDS therapy HIV infections antiAIDS agent antiviral agents clinical research clinical trials combination chemotherapy drug resistance drug screening /evaluation human subject human therapy evaluation zidovudine

项目摘要

项目成果

Martin H Markowitz的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The objectives of this study are: 1. To evaluate the safety and antiviral activity of monotherapy with ABT-538 at a dose of 600 mg BID, monotherapy with AZT at a dose of 200mg TID and a combination therapy with ABT-538 and AZT in HIV infected patients; 2. To study emergence of resistance to ABT-538. All patients participating in this trial will be allowed to cross over to the ABT-538 arm of the trial and will be continued to be monitored for virological data.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A preclinical assessment of monthly intramuscular GSK1265744, an InSTI, as PrEP
Correlates and Consequences of Increased Immune Activation in HIV + and - IDUs
Correlates and Consequences of Increased Immune Activation in HIV + and - IDUs
Correlates and Consequences of Increased Immune Activation in HIV + and - IDUs
海外基金